COPD is increasingly recognized as a complex systemic disorder with a whole range of
comorbidities, especially cardiovascular, contributing significantly to COPD morbidity and …

The long-term use of inhaled anticholinergic agents has recently been suggested to be
associated with an excess risk of adverse cardiovascular (CV) outcomes in patients with …

Review: inhaled anticholinergics increase risk of major cardiovascular events in COPD. -
Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About …

There has been recent uncertainty about whether the inhaled anticholinergic agents
ipratropium bromide and tiotropium bromide increase or decrease cardiovascular risk in the …

The treatment of COPD worldwide relies on a rather limited selection of pharmacologic
principles. Symptomatic benefit and improvement of lung function are afforded by β 2 …

Context Inhaled anticholinergics (ipratropium bromide or tiotropium bromide) are widely
used in patients with chronic obstructive pulmonary disease (COPD) but their effect on the …

Chronic obstructive pulmonary disease (COPD) is a common condition affecting men and
women equally that worsens quality of life and increases mortality. The burden of illness …

The majority of deaths in COPD are from cardiovascular causes. Several large randomized
controlled trials demonstrate that inhaled anticholinergic agents ipratropium and tiotropium …

The majority of deaths in COPD are from cardiovascular causes. Several large randomized
controlled trials demonstrate that inhaled anticholinergic agents ipratropium and tiotropium …

A meta-analysis recently published in the Journal of the American Medical Association
found an increased risk of nonfatal myocardial infarction, stroke, and cardiovascular death …